10/19/2021

PharmaTher Engages Alcami for Clinical and Commercial Manufacturing of Novel Ketamine Products

Leading U.S.-based CDMO to manufacture PharmaTher’s proprietary ketamine products for FDA Phase 3 clinical studies and global commercialization.
Expected FDA clinical and commercial supply in H2-2022.
Unlocking potential partnership opportunities with research labs, clinics and pharmaceutical companies globally.

10/13/2021

PharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Complex Regional Pain Syndrome

Achieving its second FDA orphan drug designation with ketamine.
Building a proprietary ketamine-based product pipeline for rare and near-rare disorders in pain and inflammation.
Seeking to enter Phase 2 clinical trial in 2022.

10/6/2021

PharmaTher Initiates Phase 2 Clinical Trial of Ketamine for the Treatment of Parkinson’s Disease

“KET-LID” trial to evaluate ketamine’s safety and efficacy in the treatment of levodopa-induced dyskinesia in patients with Parkinson’s disease

TORONTO, October 6, 2021 -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, announced today that it has initiated its Phase 2 KET-LID clinical trial of Ketamine for the treatment of Levodopa-Induced Dyskinesia in Subjects with Parkinson’s Disease. Patient screening and enrollment is expected to begin in October 2021 with data anticipated in late-Q4 2021.

Press Releases

PharmaTher Engages Alcami for Clinical and Commercial Manufacturing of Novel Ketamine Products

PharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Complex Regional Pain Syndrome

PharmaTher Initiates Phase 2 Clinical Trial of Ketamine for the Treatment of Parkinson’s Disease

Archives

Categories

COMPANY / RESEARCH / INVESTORS / NEWS / CONTACT